---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-26-000048"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2026-10-13T10:19:25+00:00"
generated_at: "2026-10-13T10:20:09.192937+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nurix Q3 FY26 revenue $673.1M on Roche collaboration; net income $549.8M, EPS $4.73

## Summary
- Revenue $673.1M vs $7.9M YoY, including $653.2M license revenue from Roche and a $10.0M Sanofi milestone.
- Net income $549.8M, or $4.73 per diluted share, vs an $86.4M net loss (-$1.03) a year ago; cash $1.1B with runway into H2 2029.
- Dosed first patient in Phase 3 DAYBreak CLL-306 testing bexobrutideg 600 mg vs pirtobrutinib in ~620 relapsed/refractory CLL/SLL patients; dual primary endpoints ORR and PFS.
- Phase 1a CLL data showed median PFS 22.1 months and 83.0% ORR; Phase 1b ORR 92.9% in BTK-pretreated/BCL2-naive patients.
- Discontinued NX-2127; NX-1607 entered Phase 1b in MSS CRC, NSCLC, CRPC and melanoma; Gilead extended a research term for a $10.0M fee.

## SEC filing metadata
- accession: 0001549595-26-000048
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2026-10-13T10:19:25+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000048/0001549595-26-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000048/nrix-20261012.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-26-000048
- JSON: https://secwatch.observer/filing/0001549595-26-000048.json
- Plain text: https://secwatch.observer/filing/0001549595-26-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.